TegoScience Inc (191420) - Total Assets
Based on the latest financial reports, TegoScience Inc (191420) holds total assets worth ₩76.38 Billion KRW (≈ $51.76 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TegoScience Inc - Total Assets Trend (2015–2025)
This chart illustrates how TegoScience Inc's total assets have evolved over time, based on quarterly financial data. Also see TegoScience Inc (191420) total market value for the company's overall valuation and market capitalisation.
TegoScience Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
TegoScience Inc's total assets of ₩76.38 Billion consist of 74.5% current assets and 25.5% non-current assets. Review how much debt does TegoScience Inc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 16.2% |
| Accounts Receivable | ₩2.14 Billion | 2.7% |
| Inventory | ₩2.06 Billion | 2.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.66 Billion | 3.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how TegoScience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See TegoScience Inc (191420) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TegoScience Inc's current assets represent 74.5% of total assets in 2025, an increase from 55.7% in 2015.
- Cash Position: Cash and equivalents constituted 16.2% of total assets in 2025, up from 3.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 2.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 3.4% of total assets.
TegoScience Inc Competitors by Total Assets
Key competitors of TegoScience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneBioTech Co. Ltd
KQ:086060
|
Korea | ₩80.28 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩575.39 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩222.34 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩98.92 Billion |
|
Komipharm International Co. Ltd
KQ:041960
|
Korea | ₩133.92 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
TegoScience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.64 | 28.26 | 15.08 |
| Quick Ratio | 1.55 | 27.37 | 14.47 |
| Cash Ratio | 0.00 | 0.00 | 1.24 |
| Working Capital | ₩20.86 Billion | ₩60.27 Billion | ₩23.30 Billion |
TegoScience Inc - Advanced Valuation Insights
This section examines the relationship between TegoScience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.35 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 48.8% |
| Total Assets | ₩78.16 Billion |
| Market Capitalization | $41.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values TegoScience Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: TegoScience Inc's assets grew by 48.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TegoScience Inc (2015–2025)
The table below shows the annual total assets of TegoScience Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩78.16 Billion ≈ $52.97 Million |
+48.83% |
| 2024-12-31 | ₩52.52 Billion ≈ $35.59 Million |
+7.37% |
| 2023-12-31 | ₩48.91 Billion ≈ $33.15 Million |
-4.77% |
| 2022-12-31 | ₩51.36 Billion ≈ $34.81 Million |
+0.70% |
| 2021-12-31 | ₩51.00 Billion ≈ $34.56 Million |
+1.19% |
| 2020-12-31 | ₩50.40 Billion ≈ $34.16 Million |
+3.77% |
| 2019-12-31 | ₩48.57 Billion ≈ $32.91 Million |
+2.12% |
| 2018-12-31 | ₩47.56 Billion ≈ $32.23 Million |
-0.05% |
| 2017-12-31 | ₩47.59 Billion ≈ $32.25 Million |
+6.59% |
| 2016-12-31 | ₩44.64 Billion ≈ $30.25 Million |
+73.31% |
| 2015-12-31 | ₩25.76 Billion ≈ $17.46 Million |
-- |
About TegoScience Inc
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.